ARS Pharmaceuticals (SPRY) News Today $12.63 +0.03 (+0.24%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$13.00 +0.38 (+2.97%) As of 03/27/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period SPRY FY2025 EPS Forecast Reduced by Cantor FitzgeraldARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research report issued on Monday, March 24th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the companyMarch 27 at 6:44 AM | marketbeat.comEquities Analysts Offer Predictions for SPRY FY2025 EarningsMarch 27 at 1:35 AM | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This YearMarch 26 at 10:20 AM | finance.yahoo.comWilliam Blair Brokers Decrease Earnings Estimates for SPRYMarch 25 at 1:13 AM | americanbankingnews.comRaymond James Financial Inc. Makes New $6.58 Million Investment in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Raymond James Financial Inc. purchased a new stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 623,281 shares of the company's stock, valued at approxMarch 24, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for SPRY FY2028 Earnings?ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Investment analysts at Leerink Partnrs lowered their FY2028 EPS estimates for ARS Pharmaceuticals in a research note issued on Thursday, March 20th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings of $1.57 perMarch 24, 2025 | marketbeat.comQ1 EPS Estimate for ARS Pharmaceuticals Reduced by AnalystARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities research analysts at William Blair reduced their Q1 2025 earnings estimates for shares of ARS Pharmaceuticals in a research report issued on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now anticipates that the compaMarch 24, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 11.5% Following Insider SellingMarch 23, 2025 | americanbankingnews.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 10,000 Shares of StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Eric Karas sold 10,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now directly owns 7,696 shares in the company, valued at approximately $107,744. This represents a 56.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 22, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 11.5% - Here's What HappenedARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 11.5% - Here's What HappenedMarch 22, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | insidermonkey.comScotiabank Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)March 22, 2025 | markets.businessinsider.comARS Pharmaceuticals’ Earnings Call Highlights Growth and ChallengesMarch 22, 2025 | msn.comARS Pharmaceuticals reports FY24 EPS 8c, consensus (56c)March 21, 2025 | markets.businessinsider.comARS Pharmaceuticals expects cash to fund operations for at least next 3 yearsMarch 21, 2025 | markets.businessinsider.comARS Pharmaceuticals (NASDAQ:SPRY) Posts Earnings Results, Beats Estimates By $0.61 EPSARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) released its earnings results on Thursday. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.61.March 21, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Better-Than-Expected EarningsARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up Following Earnings BeatMarch 21, 2025 | marketbeat.comARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges AwaitMarch 20, 2025 | seekingalpha.comARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call TranscriptMarch 20, 2025 | seekingalpha.comARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 20, 2025 | finanznachrichten.deARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.March 20, 2025 | investors.comARS Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call PresentationMarch 20, 2025 | seekingalpha.comARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 20, 2025 | globenewswire.comRoyce & Associates LP Acquires 238,158 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Royce & Associates LP raised its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 34.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 929,613 shares of the company's stockMarch 19, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.8% Higher - Here's WhyARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 5.8% - Still a Buy?March 13, 2025 | marketbeat.comARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on ThursdayARS Pharmaceuticals (NASDAQ:SPRY) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=672158)March 13, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 49,600 SharesARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Laura Shawver sold 49,600 shares of the firm's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $11.21, for a total transaction of $556,016.00. Following the completion of the sale, the director now directly owns 210,346 shares of the company's stock, valued at approximately $2,357,978.66. This represents a 19.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.March 8, 2025 | marketbeat.comScotiabank Initiates Coverage of ARS Pharmaceuticals (SPRY) with Sector Outperform RecommendationMarch 8, 2025 | msn.comScotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)Scotiabank assumed coverage on ARS Pharmaceuticals in a research note on Friday. They set a "sector outperform" rating and a $30.00 price target for the company.March 8, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Buy" by BrokeragesShares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have earned an average rating of "Buy" from the seven analysts that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recomMarch 8, 2025 | marketbeat.comARS Pharma : FDA Approves Neffy 1 Mg For Type I Allergic Reactions In Pediatric PatientsMarch 7, 2025 | nasdaq.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 5.5% - What's Next?ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 5.5% - Should You Buy?March 7, 2025 | marketbeat.comARS Pharmaceuticals initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY) and Corbus Pharmaceuticals (CRBP)March 6, 2025 | markets.businessinsider.comUS FDA expands use of allergic reaction nasal spray in people between 15-30 kilogramsMarch 5, 2025 | reuters.comARS Pharmaceuticals announces FDA approval for neffy 1 mgMarch 5, 2025 | markets.businessinsider.comARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 KilogramsMarch 5, 2025 | globenewswire.comARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming ConferencesMarch 3, 2025 | globenewswire.comARS Pharmaceuticals (NASDAQ:SPRY) Given Outperform Rating at William BlairWilliam Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday.March 3, 2025 | marketbeat.comLevin Capital Strategies L.P. Buys 168,201 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Levin Capital Strategies L.P. grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 56.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 467,627 shares of the companMarch 2, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Earns "Outperform" Rating from William BlairWilliam Blair restated an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Friday.February 22, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Has $3.63 Million Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Allspring Global Investments Holdings LLC increased its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 93.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34February 21, 2025 | marketbeat.comARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for PatientsFebruary 20, 2025 | globenewswire.comPeregrine Capital Management LLC Invests $4.47 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Peregrine Capital Management LLC acquired a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 423,561 shares of the company's stoFebruary 20, 2025 | marketbeat.comARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific MeetingFebruary 18, 2025 | globenewswire.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by AnalystsShares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven research firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and two have given a strong buy ratinFebruary 11, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up - Here's WhyARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up - Time to Buy?February 10, 2025 | marketbeat.comARS Pharmaceuticals initiated with an Outperform at OppenheimerFebruary 10, 2025 | markets.businessinsider.comOppenheimer Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)Oppenheimer assumed coverage on shares of ARS Pharmaceuticals in a report on Monday. They set an "outperform" rating and a $40.00 target price on the stock.February 10, 2025 | marketbeat.comARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare ConferenceFebruary 6, 2025 | finance.yahoo.com Remove Ads Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRY Media Mentions By Week SPRY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼0.300.78▲Average Medical News Sentiment SPRY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼285▲SPRY Articles Average Week Remove Ads Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADMA News Today PTCT News Today RNA News Today ACLX News Today OGN News Today ZLAB News Today SWTX News Today RARE News Today AKRO News Today ALVO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRY) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRY Stock Free SPRY Stock Alerts